Your browser doesn't support javascript.
loading
Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults.
Zhang, Yongkang; Romieu-Hernandez, Alfonso; Boehmer, Tegan K; Azziz-Baumgartner, Eduardo; Carton, Thomas W; Gundlapalli, Adi V; Fearrington, Julia; Nagavedu, Kshema; Dea, Katherine; Moyneur, Erick; Cowell, Lindsay G; Kaushal, Rainu; Mayer, Kenneth H; Puro, Jon; Rasmussen, Sonja A; Thacker, Deepika; Weiner, Mark G; Saydah, Sharon; Block, Jason P.
Afiliação
  • Zhang Y; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
  • Romieu-Hernandez A; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Boehmer TK; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Azziz-Baumgartner E; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Carton TW; Louisiana Public Health Institute, New Orleans, LA, USA.
  • Gundlapalli AV; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Fearrington J; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA, USA.
  • Nagavedu K; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA, USA.
  • Dea K; Statlog, Montreal, Canada.
  • Moyneur E; Statlog, Montreal, Canada.
  • Cowell LG; Peter O-Donnell Jr. School of Public Health, Department of Immunology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Kaushal R; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
  • Mayer KH; Fenway Institute, Fenway Health, Harvard Medical School, Boston, MA, USA.
  • Puro J; OCHIN, Inc., Portland, OR, USA.
  • Rasmussen SA; Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA.
  • Thacker D; Nemours Cardiac Center, Nemours Children's Health, Wilmington, Delaware, USA.
  • Weiner MG; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
  • Saydah S; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Block JP; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA, USA. jblock1@partners.org.
BMC Infect Dis ; 24(1): 181, 2024 Feb 10.
Article em En | MEDLINE | ID: mdl-38341566
ABSTRACT

BACKGROUND:

An increasing number of studies have described new and persistent symptoms and conditions as potential post-acute sequelae of SARS-CoV-2 infection (PASC). However, it remains unclear whether certain symptoms or conditions occur more frequently among persons with SARS-CoV-2 infection compared with those never infected with SARS-CoV-2. We compared the occurrence of specific COVID-associated symptoms and conditions as potential PASC 31- to 150-day following a SARS-CoV-2 test among adults and children with positive and negative test results.

METHODS:

We conducted a retrospective cohort study using electronic health record (EHR) data from 43 PCORnet sites participating in a national COVID-19 surveillance program. This study included 3,091,580 adults (316,249 SARS-CoV-2 positive; 2,775,331 negative) and 675,643 children (62,131 positive; 613,512 negative) who had a SARS-CoV-2 laboratory test during March 1, 2020-May 31, 2021 documented in their EHR. We used logistic regression to calculate the odds of having a symptom and Cox models to calculate the risk of having a newly diagnosed condition associated with a SARS-CoV-2 positive test.

RESULTS:

After adjustment for baseline covariates, hospitalized adults and children with a positive test had increased odds of being diagnosed with ≥ 1 symptom (adults adjusted odds ratio[aOR], 1.17[95% CI, 1.11-1.23]; children aOR, 1.18[95% CI, 1.08-1.28]) or shortness of breath (adults aOR, 1.50[95% CI, 1.38-1.63]; children aOR, 1.40[95% CI, 1.15-1.70]) 31-150 days following a SARS-CoV-2 test compared with hospitalized individuals with a negative test. Hospitalized adults with a positive test also had increased odds of being diagnosed with ≥ 3 symptoms or fatigue compared with those testing negative. The risks of being newly diagnosed with type 1 or type 2 diabetes (adjusted hazard ratio[aHR], 1.25[95% CI, 1.17-1.33]), hematologic disorders (aHR, 1.19[95% CI, 1.11-1.28]), or respiratory disease (aHR, 1.44[95% CI, 1.30-1.60]) were higher among hospitalized adults with a positive test compared with those with a negative test. Non-hospitalized adults with a positive test also had higher odds or increased risk of being diagnosed with certain symptoms or conditions.

CONCLUSIONS:

Patients with SARS-CoV-2 infection, especially those who were hospitalized, were at higher risk of being diagnosed with certain symptoms and conditions after acute infection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Revista: BMC Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Revista: BMC Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos